Learn More
  • Shengri Liao, Bill C Penney, Kristen Wroblewski, Hao Zhang, Cassie A Simon, Rony Kampalath +24 others
  • 2011
Purpose The objective of this study was to assess the prognostic value of metabolic tumor burden on 2-deoxy-2-[ 18 F]fluoro-D-glucose (18 F-FDG) positron emission tomog-raphy (PET)/CT measured with metabolic tumor volume (MTV) and total lesion glycolysis (TLG), independent of Union Internationale Contra la Cancrum (UICC)/American Joint Committee on Cancer(More)
PURPOSE To determine whether whole-body metabolic tumor burden, measured as either metabolic tumor volume (MTVWB) or total lesion glycolysis (TLGWB), using FDG-PET/CT is an independent prognostic marker in non-small cell lung cancer (NSCLC). METHODS 328 patients with histologically proven NSCLC were identified for this retrospective analysis. This study(More)
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression. Preclinical evidence suggests that baseline elevated tumor glucose metabolism as quantified by FDG-PET ([(18)F] fluorodeoxy-glucose positron emission tomography) may(More)
BACKGROUND Studies suggest that patients with metastases limited in number and destination organ benefit from metastasis-directed therapy. Stereotactic body radiotherapy (SBRT) is commonly used for metastasis directed therapy in this group. However, the characterization of PET response following SBRT is unknown in this population. We analyzed our cohort of(More)
Background: 18 F-FDG PET standardized uptake values (SUV) is important for the diagnosis and follow-up for lymphoma patients. However, numerous patient-and technique-related factors could affect the measurement of SUV. This study was performed to determine the inter-observer variability of 18 F-FDG PET SUV in lym-phoma patients. To our knowledge, there is(More)
It is unclear whether patients with spinocerebellar ataxia type 6 (SCA6) have parkinsonism and striatal dopamine transporter (DAT) loss, based on previously small size studies without well-matched controls. A study with a larger number of patients and both age- and gender-matched healthy controls (HCs) is needed for a better answer to this question. Twelve(More)
BACKGROUND AND PURPOSE The differential diagnosis in single or oligo-brain lesions in metastatic cancer patients remains broad. Advanced imaging studies can be employed to help refine the differential and potentially guide treatment. METHODS Case report of a 52-year-old male patient with known transitional cell carcinoma of the bladder presented with(More)
In order to aid radiologists' routine work for interpreting bone scan images, we developed a computerized method for temporal subtraction (TS) images which can highlight interval changes between successive whole-body bone scans, and we performed a prospective clinical study for evaluating the clinical utility of the TS images. We developed a TS image server(More)
The authors report the fluorodeoxyglucose (FDG)-positron emission tomography(PET)/computed tomography (CT) findings of a rare case of growth hormone-secreting pituitary carcinoma with multiple metastatic lesions to the skeleton. A 31-year-old male had presented with acromegaly and had received transsphenoidal resection of a pituitary tumor and adjuvant(More)
  • 1